Latest Tarenflurbil Stories
Vanderbilt University investigators have discovered surprising new insights into the actions of NSAIDs.
Although there were promising results in a phase 2 trial, patients with mild Alzheimer disease who received the drug tarenflurbil as part of a phase 3 trial did not have better outcomes on measures of cognitive decline or loss of activities of daily living compared to patients who received placebo, according to a study in the December 16 issue of JAMA.
Eli Lilly and Company has announced that it will begin enrolling patients in a second Phase III study of LY450139, a gamma-secretase inhibitor being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer's disease.
By Lois M. Collins Deseret News Researchers at the University of Utah are looking for volunteers who have mild to moderate Alzheimer's disease to test a drug that may slow its associated decline.
U.S. medical scientists say a drug commonly prescribed to treat immunodeficiencies has shown promise as a treatment for Alzheimer's disease.
By Jeremy Manier, Chicago Tribune Jul. 31--Editor's note: Due to a production error, this story from Wednesday's newspaper did not run in full. This is the complete text.
An experimental Alzheimerâ€™s drug shows promise in halting progression of the disease through a new approach of dissolving the protein tangles that form in victimsâ€™ brain.